Blog

With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...

MUNICH/DRESDEN, April 6, 2022—NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help...

Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...

NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....

SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...

Reproducibility is a key tenet of scientific research, but many pharma groups have projects that collaborate across different sites or that rely on materials prepared by other specialist...

Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...

With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

Biologics researchers are deeply concerned with formulation. Formulation typically refers to the final development of a deliverable, biologically derived molecule (such as a protein, peptide,...

NanoTemper has been given this year’s TOP 100 seal, an award that honors innovative German small and medium-sized companies. The TOP 100 innovation competition is organized by compamedia, and...

NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal of excellence in design. Both bold aesthetics and user-friendly design have always...

SOUTH SAN FRANCISCO, Calif. June 24, 2021 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, enters the protein production market with...

Biologics, which are drugs and treatments derived from natural products, undergo a long development process before they reach the clinic. When you invest a lot of time and money in the process to...

NanoTemper Technologies and SIRION Biotech, two of Munich’s rapidly growing biotech companies, are lending their support to Adrian Bleninger, a 30-year-old Bavarian sailor, in his bid to qualify...

For the second year in a row, NanoTemper was named one of the most innovative companies in Germany by Capital magazine. A five out of five star distinction placed NanoTemper in the ranking’s top...

There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly design has always been a core focus in NanoTemper’s product development....

Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...